" class="no-js "lang="en-US"> Riccardo Canevari - Medtech Alert
Saturday, July 19, 2025
Riccardo Canevari

Riccardo Canevari

About Riccardo Canevari

Riccardo has broad and deep experience across specialty pharma, oncology and radiopharmaceuticals.  He was most recently Chief Commercial Officer of Novartis company Advanced Accelerator Applications, one of the leading radiopharmaceutical and nuclear medicine companies globally. He was responsible for global commercial strategy and country organisations in ~20 countries across North America, Europe and Asia.  He was lead for Lutathera in-market growth strategy and execution to build a blockbuster asset and lead on the prelaunch plan for Lu-PSMA 617 in metastatic prostate cancer.  He assessed Go To Market Models for each priority country and access to other markets.  Prior to this Riccardo was Senior Vice President and Global Head, Breast Cancer Franchise for Novartis Oncology since 2017, overseeing the launch of major breast cancer produincludingcts  KISQALI and PIQRAY.  He has also held various management roles with Novartis Pharma and Ethicon/Johnson&Johnson.

Related Story

Radiopharm Enters Into Strategic Collaboration With Lantheus and Assumes PD-L1 Licensing Agreement From Nanomab

August 4 2022

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical […]

RAD Adds Brain Tumor Technology to Portfolio

June 10 2022

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a world-class developer of cutting-edge radiopharmaceutical products for […]